Oncolytics Biotech (TSE:ONC) Hits New 12-Month Low – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as C$1.15 and last traded at C$1.17, with a volume of 121921 shares traded. The stock had previously closed at C$1.18.

Analysts Set New Price Targets

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Price Performance

The stock has a market capitalization of C$84.55 million, a P/E ratio of -2.89 and a beta of 1.35. The company has a 50 day moving average of C$1.48 and a 200-day moving average of C$1.41. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.